BEIJING, Aug. 31, 2016 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq:KANG), the largest provider in China’s fast growing private preventive healthcare services market with a market share of 13.6% in terms of revenue in calendar year 2014, today announced its unaudited financial results for the first quarter ended June 30, 2016.
Fiscal First Quarter Ended June 30, 2016 Financial Highlights
- Net revenues were US$101.2 million, an increase of 17.3% year-over-year (an increase of 23.5% on RMB basis) (1)
- Gross profit was US$44.7 million, an increase of 6.1% year-over-year (an increase of 11.8% on RMB basis) (1)
- Net income attributable to the Company was US$2.1 million, a decrease of 80.6% year-over-year (a decrease of 79.6% on RMB basis) (1)
- Non-GAAP net income attributable to the Company(2) was US$2.6 million, a decrease of 77.1% year-over-year (a decrease of 75.9% on RMB basis) (1)
- Basic and diluted income per ADS attributable to common shareholders were US$0.03 and US$0.03, respectively, as compared to US$0.16 and US$0.15, respectively, in the fiscal first quarter of 2015
- Non-GAAP basic and diluted income per ADS(3) attributable to common shareholders were US$0.04 and US$0.04, respectively, as compared to US$0.16 and US$0.16, respectively, in the fiscal first quarter of 2015
(1) RMB basis refers to the year on year comparison made on local currency – Chinese Renminbi basis.
(2) Non-GAAP net income attributable to the Company is defined as net income attributable to the Company excluding share-based compensation expenses. For more information on these non-GAAP financial measures, please see the section captioned under “Non-GAAP Financial Measures” and the tables captioned “Reconciliation of GAAP and Non-GAAP Results” set forth at the end of this release.
(3) Non-GAAP basic and diluted earnings per ADS is defined as non-GAAP net income divided by the weighted average number of basic and diluted ADS.
Mr. Lee Ligang Zhang, Chairman and Chief Executive Officer of iKang, commented on the results. “iKang recorded a solid performance in the fiscal first quarter of 2016, with overall revenue growth of 23.5% year-over-year. This increase, spread over a broader customer base, indicates a positive direction for the Company to expand as we continue to execute our strategic priorities of investing in sustainable, long term growth.”
“Over the past quarter, iKang has invested in a number of market initiatives to expand our geographical coverage and deepen market penetration in fast-growing tier two and three cities. Compared to June 30, 2015, we have added 19 new medical centers and expanded into seven new cities – Weihai, Weifang, Xi’an, Wuhu, Guiyang, Ningbo and Foshan – bringing our network to 92 medical centers as of August 31, 2016. We have also invested in new service offerings for our expanding network and remain focused on investing in the renovation, upgrade and ramping up of our acquired medical centers.”
Mr. Zhang concluded, “amid an economic slowdown, the management remains fully committed to executing our dual expansion strategy that aligns acquisitions and investments with a self-built model to advance network expansion. iKang will continue to leverage this initiative to capture the tremendous opportunities prevalent in the fast-growing Chinese private preventative healthcare services market while delivering profitable and sustainable business growth.”
Fiscal First Quarter ended June 30, 2016 UNAUDITED FINANCIAL RESULTS
Net Revenues
Net revenues for the fiscal first quarter were US$101.2 million, representing a 17.3% increase from US$86.3 million in the same period of the last fiscal year. As of June 30, 2016, the number of self-owned medical centers totaled 90 compared to 73 as of June 30, 2015. In the quarter, the Company served approximately a total of 1,264,600 customer visits under both corporate and individual programs, representing an increase of 22.0% over the fiscal first quarter of 2015.
The table below sets forth a breakdown of net revenues:
| (US$ million) | 1st Fiscal Quarter Ended June 30, 2016 | 1st Fiscal Quarter Ended June 30, 2015 | YoY % Change | ||
| Medical Examinations | 85.0 | 72.0 | 18.0 | % | |
| Disease Screening | 7.3 | 5.5 | 32.4 | % | |
| Dental Services | 1.3 | 1.5 | -17.7 | % | |
| Other Services | 7.6 | 7.3 | 6.3 | % | |
| Total | 101.2 | 86.3 | 17.3 | % | |
Medical Examinations: Net revenues for the quarter were US$85.0 million, representing an 18.0% increase from US$72.0 million in the same period of the last fiscal year, which was in line with the increase in the number of visits.
Disease Screening: Net revenues for the quarter were US$7.3 million, representing a 32.4% increase from US$5.5 million in the same period of the last fiscal year. Disease screening services refer to the additional services requested by individuals under the basic corporate medical examination programs as a result of individual needs.
Dental Services: Net revenues for the quarter were US$1.3 million, representing a 17.7% decrease from US$1.5 million in the same period of the last fiscal year.
Other Services: Net revenues for the quarter were US$7.6 million, representing a 6.3% increase from US$7.3 million in the same period of the last fiscal year.
Cost of Revenues
Cost of revenues for the quarter was US$56.5 million, representing a 28.0% increase from US$44.2 million in the same period of the last fiscal year.
Gross Profit and Gross Margin
Gross profit for the quarter was US$44.7 million, representing a 6.1% increase from US$42.1 million in the same period of the last fiscal year. Gross margin for the quarter was 44.2%, as compared to 48.8% in the first quarter of fiscal 2015. Gross margin was diluted mainly due to the addition of newly acquired medical centers which have lower gross margins, as they were still in their ramping up period.
Operating Expenses
Total operating expenses for the quarter were US$37.9 million, representing a 36.7% increase from US$27.7 million in the same period of the last fiscal year.
Selling and marketing expenses
Selling and marketing expenses for the quarter were US$18.3 million, accounting for 18.1% of total net revenues as compared to 16.3% in the same period of the last fiscal year. The increase was mainly in personnel cost as a result of the sales and marketing team expansion in both existing and new geographic areas.
General and administrative expenses
General and administrative expenses for the quarter were US$18.7 million, accounting for 18.5% of total net revenues as compared to 15.0% in the same period of the last fiscal year. The increase was mainly in payroll and rental costs which were associated with our expansion into new geographic areas. The professional service expenses relating to the “going private” process also contributed the increases.
Research and development expenses
Research and development expenses for the quarter were US$884,000, accounting for 0.9% of total net revenues as compared to 0.8% in the same period of the last fiscal year, which reflected our increasing investment in information technology infrastructure and mobile health app.
Income from Operations
Income from operations for the quarter was US$6.8 million, representing a 52.6% decrease from US$14.4 million in the same period of the last fiscal year. Excluding share-based compensation expenses of US$484,000 for this quarter and US$492,000 for the same quarter last year, non-GAAP income from operations for the quarter was US$7.3 million as compared to US$14.9 million, which reflected a decline of 50.9% as a result of diluted gross margin and an increase in operating expenses.
Net Income
Net income attributable to the Company for the quarter was US$2.1 million, representing a decrease of 80.6% from US$10.7 million for the same period in the last fiscal year.
Non-GAAP net income for the quarter was US$2.6 million, representing a decrease of 77.1% from US$11.2 million for the same period in fiscal 2015.
Basic and Diluted Earnings per ADS
Basic and diluted income per ADS attributable to common shareholders were US$0.03 and US$0.03, respectively, compared to basic and diluted income per ADS attributable to common shareholders of US$0.16 and US$0.15, respectively, in the same quarter of fiscal 2015.
Non-GAAP basic and diluted income per ADS attributable to common shareholders were US$0.04 and US$0.04, respectively, compared to basic and diluted income per ADS attributable to common shareholders of US$0.16 and US$0.16, respectively, in the same quarter of fiscal 2015.
STATEMENT REGARDING UNAUDITED FINANCIAL INFORMATION
The unaudited financial information set forth above is subject to adjustments that may be identified when audit work is performed on the Company’s year-end financial statements, which could result in significant differences from this unaudited financial information.
NON-GAAP FINANCIAL MEASURES
To supplement our consolidated financial statements which are presented in accordance with U.S. GAAP, we also use non-GAAP operating income, non-GAAP net income and non-GAAP EBITDA as additional non-GAAP financial measures. We present these non-GAAP financial measures because they are used by our management to evaluate our operating performance. We also believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our consolidated results of operations in the same manner as our management and in comparing financial results across accounting periods and to those of our peer companies.
Reconciliation of non-GAAP operating income, non-GAAP net income and non-GAAP EBITDA to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP is set forth at the end of this release.
About iKang Healthcare Group, Inc.
iKang Healthcare Group, Inc. is the largest provider in China’s fast growing private preventive healthcare services market, accounting for approximately 13.6% of market share in terms of revenue in calendar year 2014.
Through iKang’s integrated service platform and established nationwide network of medical centers and third-party service provider facilities, the Company provides comprehensive and high quality preventive healthcare solutions, including a wide range of medical examinations services and value-added services including disease screening and other services. iKang’s customers are primarily corporate customers who contract with the Company to provide medical examination services to their employees and clients, and pay for these services at pre-negotiated prices. iKang also directly markets its services to individual customers. In the fiscal year ended March 31, 2016, the Company served a total of 4.6 million customer visits under both corporate and individual programs.
As of August 31, 2016, iKang’s nationwide network consisted of 92(1) self-owned medical centers covering 27 of the most affluent cities in China, namely Beijing, Shanghai, Guangzhou, Shenzhen, Chongqing, Tianjin, Nanjing, Suzhou, Hangzhou, Chengdu, Fuzhou, Changchun, Jiangyin, Changzhou, Wuhan, Changsha, Yantai, Yinchuan, Weihai, Weifang, Shenyang, Xi’an, Wuhu, Guiyang, Ningbo and Foshan as well as Hong Kong. The Company has also supplemented its self-owned medical center network by contracting with approximately 400 third-party service provider facilities in over 150 cities, which include select independent medical examination centers and hospitals across all of China’s provinces, creating a nationwide network that allows iKang to serve its customers in markets where it does not have self-owned medical centers.
(1) Among the 92 self-owned medical centers, two medical centers are currently operated primarily by the minority shareholders of these medical centers or their parent company.
Forward-looking Statements
This press release contains forward-looking statements. These statements, including management quotes and business outlook, are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as ”will,” "estimate," "project," "predict," "believe," "expect," "anticipate," "intend," "potential," "plan," "goal" and similar statements. iKang may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company’s goals and strategies; its future business development, financial condition and results of operations; its ability to retain and grow its customer base and network of medical centers; the growth of, and trends in, the markets for its services in China; the demand for and market acceptance of its brand and services; competition in its industry in China; relevant government policies and regulations relating to the corporate structure, business and industry; fluctuations in general economic and business conditions in China. Further information regarding these and other risks is included in iKang’s filing with the Securities and Exchange Commission. iKang undertakes no duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
| IKANG HEALTHCARE GROUP, INC. | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| (In thousands of US dollars, except share data and per share data) | |||||||
| (Unaudited) | |||||||
| As of | As of | ||||||
| March 31, | June 30, | ||||||
| 2016 | 2016 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 108,111 | $ | 62,067 | |||
| Restricted cash | 31,836 | 27,847 | |||||
| Term deposits | 12,202 | - | |||||
| Accounts receivable, net of allowance for doubtful accounts of $14,329 | 74,163 | 97,682 | |||||
| and $14,874 as of March 31, 2016 and June 30, 2016, respectively | |||||||
| Inventories | 4,015 | 4,236 | |||||
| Deferred tax assets-current | 8,064 | 8,218 | |||||
| Amount due from a related party | 4,653 | 5,488 | |||||
| Prepaid expenses and other current assets | 62,659 | 65,132 | |||||
| Total current assets | $ | 305,703 | $ | 270,670 | |||
| Property and equipment, net | $ | 130,170 | $ | 134,439 | |||
| Acquired intangible assets, net | 37,179 | 33,886 | |||||
| Goodwill | 108,839 | 110,656 | |||||
| Long-term investments | 200,108 | 194,565 | |||||
| Deferred tax assets-non-current | 8,077 | 9,054 | |||||
| Rental deposit and other non-current assets | 13,565 | 14,669 | |||||
| TOTAL ASSETS | $ | 803,641 | $ | 767,939 | |||
| LIABILITIES, MEZZANINE EQUITY AND EQUITY (DEFICIT) | |||||||
| Current liabilities: | |||||||
| Accounts payable (including accounts payable of the consolidated VIEs | |||||||
| without recourse to iKang Healthcare Group, Inc. of $22,685 | |||||||
| and $24,873 as of March 31, 2016 and June 30, 2016, respectively) | $ | 28,135 | $ | 30,467 | |||
| Accrued expenses and other current liabilities (including accrued expenses | |||||||
| and other current liabilities of the consolidated VIEs without recourse | |||||||
| to iKang Healthcare Group, Inc. of $41,319 and $38,897 as of March 31, 2016 | |||||||
| and June 30, 2016, respectively) | 47,404 | 47,797 | |||||
| Income tax payable (including income tax payable of the consolidated VIEs | |||||||
| without recourse to iKang Healthcare Group, Inc. of $7,386 and | |||||||
| $5,655 as of March 31, 2016 and June 30, 2016, respectively) | 8,216 | 6,932 | |||||
| Deferred revenues (including deferred revenues of the consolidated VIEs | |||||||
| without recourse to iKang Healthcare Group, Inc. of $52,210 and | |||||||
| $53,169 as of March 31, 2016 and June 30, 2016, respectively) | 61,881 | 63,765 | |||||
| Short term borrowings (including short term borrowings of the consolidated | |||||||
| VIEs without recourse to iKang Healthcare Group, Inc. of $53,364 | |||||||
| and $30,769 as of March 31, 2016 and June 30, 2016, respectively) | 53,364 | 30,769 | |||||
| Total current liabilities | $ | 199,000 | $ | 179,730 | |||
| IKANG HEALTHCARE GROUP, INC. | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS - continued | |||||||
| (In thousands of US dollars, except share data and per share data) | |||||||
| (Unaudited) | |||||||
| As of | As of | ||||||
| March 31, | June 30, | ||||||
| 2016 | 2016 | ||||||
| Long-term borrowings (including long term borrowings of the consolidated | |||||||
| VIEs and VIEs’ subsidiaries without recourse to iKang Healthcare Group, Inc. | |||||||
| of $229,467 and $226,170 as of March 31, 2016 and June 30, 2016, respectively) | 229,467 | 226,170 | |||||
| Deferred tax liabilities-non-current (including deferred tax liabilities | |||||||
| non-current of the consolidated VIEs without recourse to iKang | |||||||
| Healthcare Group, Inc. of $9,422 and $8,806 as of March 31, 2016 and | |||||||
| June 30, 2015, respectively) | 9,772 | 9,091 | |||||
| TOTAL LIABILITIES | $ | 438,239 | $ | 414,991 | |||
| Equity: | |||||||
| Total iKang Healthcare Group, Inc. shareholders' equity | 342,826 | 330,666 | |||||
| Non-controlling interests | 22,576 | 22,282 | |||||
| TOTAL EQUITY | 365,402 | 352,948 | |||||
| TOTAL LIABILITIES AND EQUITY | $ | 803,641 | $ | 767,939 | |||
| IKANG HEALTHCARE GROUP, INC. | |||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
| (In thousands of US dollars, except share data and per share data) | |||||||
| (Unaudited) | |||||||
| Three-month periods | |||||||
| ended June 30, | |||||||
| 2015 | 2016 | ||||||
| Net revenues | $ | 86,297 | $ | 101,238 | |||
| Cost of revenues | 44,152 | 56,505 | |||||
| Gross profit | $ | 42,145 | $ | 44,733 | |||
| Operating expenses: | |||||||
| Selling and marketing expenses | $ | 14,031 | $ | 18,301 | |||
| General and administrative expenses | 12,967 | 18,702 | |||||
| Research and development expenses | 717 | 884 | |||||
| Total operating expenses | $ | 27,715 | $ | 37,887 | |||
| Income from operations | $ | 14,430 | $ | 6,846 | |||
| Interest expenses | (396 | ) | (3,281 | ) | |||
| Interest income | 186 | 376 | |||||
| Income before income tax expenses and gain from | |||||||
| equity method investments | $ | 14,220 | $ | 3,941 | |||
| Income tax expenses | 3,783 | 985 | |||||
| Loss from equity method investments | - | (1,037 | ) | ||||
| Net income | $ | 10,437 | $ | 1,919 | |||
| Less: Net loss attributable to non-controlling interests | (225 | ) | (147 | ) | |||
| Net income attributable to iKang Healthcare Group, Inc. | $ | 10,662 | $ | 2,066 | |||
| Net income attributable to common shareholders | |||||||
| of iKang Healthcare Group, Inc. | $ | 10,662 | $ | 2,066 | |||
| Net income per share attributable to common shareholders | |||||||
| of iKang Healthcare Group, Inc. | |||||||
| Basic | $ | 0.31 | $ | 0.06 | |||
| Diluted | $ | 0.30 | $ | 0.06 | |||
| Net income per ADS (one common share equals to two ADSs) | |||||||
| Basic | $ | 0.16 | $ | 0.03 | |||
| Diluted | $ | 0.15 | $ | 0.03 | |||
| Weighted average shares used in calculating net income | |||||||
| per common share | |||||||
| Basic | 34,361,539 | 33,955,067 | |||||
| Diluted | 35,290,545 | 34,654,762 | |||||
| IKANG HEALTHCARE GROUP, INC. | |||||||
| RECONCILIATION OF GAAP AND NON-GAAP RESULTS | |||||||
| (In thousands of US dollars, except share data and per share data) | |||||||
| (Unaudited) | |||||||
| Three-month periods | |||||||
| ended June 30, | |||||||
| 2015 | 2016 | ||||||
| Income from operations | $ | 14,430 | $ | 6,846 | |||
| Add: | |||||||
| Share-based compensation expenses | 492 | 484 | |||||
| Non-GAAP operating income | $ | 14,922 | $ | 7,330 | |||
| Net income attributable to iKang Healthcare Group, Inc. | $ | 10,662 | $ | 2,066 | |||
| Add: | |||||||
| Share-based compensation expenses | 492 | 484 | |||||
| Non-GAAP net income | $ | 11,154 | $ | 2,550 | |||
| Income from operations | $ | 14,430 | $ | 6,846 | |||
| Add: | |||||||
| Depreciation and amortization | 6,776 | 8,647 | |||||
| Share-based compensation expenses | 492 | 484 | |||||
| Non-GAAP EBITDA | $ | 21,698 | $ | 15,977 | |||
| Non-GAAP net income attributable to common shareholders | |||||||
| of iKang Healthcare Group, Inc. | $ | 11,154 | $ | 2,550 | |||
| Non-GAAP net income per share attributable to common shareholders | |||||||
| of iKang Healthcare Group, Inc. | |||||||
| Basic | $ | 0.33 | $ | 0.08 | |||
| Diluted | $ | 0.32 | $ | 0.07 | |||
| Non-GAAP net income per ADS (one common share equals to two ADSs) | |||||||
| Basic | $ | 0.16 | $ | 0.04 | |||
| Diluted | $ | 0.16 | $ | 0.04 | |||